Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-03-11 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Lupin Limited has received FDA approval for a generic drug (Vigabatrin for Oral Solution USP). It contains no financial statements, no detailed financial data, no regulatory certifications, or meeting materials. It is a corporate announcement about a product approval, not a financial report or regulatory filing. The document length is short (2464 characters), and it is clearly a press release rather than a report or announcement of a report publication. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement or corporate news that does not fit other categories.
2022-03-11 English
Lupin Launches its First Reference Laboratory in East India Establishing its Diagnostics Business in Kolkata.
Regulatory Filings
2022-03-10 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated March 10, 2022, from Lupin Limited announcing the launch of its first Reference Laboratory in East India. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content is a business update about a new diagnostics facility and does not contain financial statements, audit information, management changes, or voting results. It is not a report or filing of financial results but a corporate announcement about business expansion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-03-10 English
Lupin Teams up with Mary Kom to Raise Awareness Amongst Women on Cardiovascular Disease.
Regulatory Filings
2022-03-09 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges disclosing a press release about a Facebook Live session hosted by Lupin Limited on International Women's Day. The content focuses on a corporate social responsibility campaign (Shakti campaign) to raise awareness about cardiovascular disease among women. There are no financial statements, regulatory filings, or management discussions of financial results. The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically covers material events or information that companies must disclose to stock exchanges. This is an announcement of a corporate event and not a financial report, audit, or management report. It is not a report publication announcement since it does not mention any report being published or attached. It is not a call transcript, earnings release, or any other financial filing. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory disclosures that do not fit other categories.
2022-03-09 English
Disclosure pursuant to grant of 8136 stock options under ESOP.
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about the grant of stock options to employees of subsidiary companies. It details the number of options granted, the exercise price, and the vesting schedule. There are no financial statements or comprehensive financial data presented. The document is an announcement related to capital changes (stock options granted), which fits the category of Share Issue/Capital Change (SHA). The document length is short and it is not a full report but an announcement of a capital-related event.
2022-03-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.